Virtual and experimental screening of new melatonin bioisosteres for the treatment of glaucoma

D. Babkov, A. Taran, A. A. Shevchenko, L. V. Naumenko, O. Zhukovskaya, A. M. Efremov, E. N. Bezsonova, N. A. Lozinskaya, A. Spasov
{"title":"Virtual and experimental screening of new melatonin bioisosteres for the treatment of glaucoma","authors":"D. Babkov, A. Taran, A. A. Shevchenko, L. V. Naumenko, O. Zhukovskaya, A. M. Efremov, E. N. Bezsonova, N. A. Lozinskaya, A. Spasov","doi":"10.29413/abs.2024-9.1.12","DOIUrl":null,"url":null,"abstract":"Background. Melatonin is an endogenous regulator of intraocular pressure (IOP), but its effectiveness as a drug for glaucoma treatment is limited.The  aim of  the  study. To develop and  to  validate a  virtual screening method to identify bioisosteric analogs of melatonin that are promising for study as agents that reduce intraocular pressure.Results. A database containing structural and experimental affinity information for 48 individual reference compounds was created. Risk assessments for mutagenic, carcinogenic, irritant and reproductive toxicity were performed in DataWarrior based on substructural analysis and identification of fragments that are markers of relevant toxicity. A virtual screening of 2457 structures was carried out and 25 compounds from the selected ones were experimentally studied for their effect on intraocular pressure (IOP) in intact rats. 10 of the 25 prioritized compounds were found to significantly reduce IOP; compound RU-398 reduced IOP by 40 %, K-165 – by 40.9 %, and RU-615 reduced glaucoma by 33.3 %.Conclusion. The  effectiveness of  virtual screening after experimental validation was 40 %. The identified active compounds are promising for further study and development as the agents for the treatment of glaucoma.","PeriodicalId":505136,"journal":{"name":"Acta Biomedica Scientifica","volume":"118 30","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Biomedica Scientifica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29413/abs.2024-9.1.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background. Melatonin is an endogenous regulator of intraocular pressure (IOP), but its effectiveness as a drug for glaucoma treatment is limited.The  aim of  the  study. To develop and  to  validate a  virtual screening method to identify bioisosteric analogs of melatonin that are promising for study as agents that reduce intraocular pressure.Results. A database containing structural and experimental affinity information for 48 individual reference compounds was created. Risk assessments for mutagenic, carcinogenic, irritant and reproductive toxicity were performed in DataWarrior based on substructural analysis and identification of fragments that are markers of relevant toxicity. A virtual screening of 2457 structures was carried out and 25 compounds from the selected ones were experimentally studied for their effect on intraocular pressure (IOP) in intact rats. 10 of the 25 prioritized compounds were found to significantly reduce IOP; compound RU-398 reduced IOP by 40 %, K-165 – by 40.9 %, and RU-615 reduced glaucoma by 33.3 %.Conclusion. The  effectiveness of  virtual screening after experimental validation was 40 %. The identified active compounds are promising for further study and development as the agents for the treatment of glaucoma.
用于治疗青光眼的新型褪黑素生物异构体的虚拟和实验筛选
背景。褪黑素是眼内压(IOP)的内源性调节剂,但其作为青光眼治疗药物的有效性有限。开发并验证一种虚拟筛选方法,以确定有望作为降低眼压药物进行研究的褪黑素生物异构类似物。建立了一个数据库,其中包含 48 种参考化合物的结构和实验亲和力信息。在 DataWarrior 中对诱变、致癌、刺激和生殖毒性进行了风险评估,评估的基础是亚结构分析和相关毒性标记片段的鉴定。对 2457 种结构进行了虚拟筛选,并对筛选出的 25 种化合物对完整大鼠眼压(IOP)的影响进行了实验研究。结果发现,25 个优先化合物中有 10 个能显著降低眼压;化合物 RU-398 降低眼压 40%,K-165 降低 40.9%,RU-615 降低青光眼 33.3%。经过实验验证,虚拟筛选的有效性为 40%。已确定的活性化合物有望作为治疗青光眼的药物得到进一步研究和开发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信